183 related articles for article (PubMed ID: 21542824)
1. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure.
McGann PT; Howard TA; Flanagan JM; Lahti JM; Ware RE
Br J Haematol; 2011 Jul; 154(1):134-40. PubMed ID: 21542824
[TBL] [Abstract][Full Text] [Related]
2. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.
Flanagan JM; Steward S; Howard TA; Mortier NA; Kimble AC; Aygun B; Hankins JS; Neale GA; Ware RE
Br J Haematol; 2012 Apr; 157(2):240-8. PubMed ID: 22360576
[TBL] [Abstract][Full Text] [Related]
3. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.
Lobo CL; Pinto JF; Nascimento EM; Moura PG; Cardoso GP; Hankins JS
Br J Haematol; 2013 Jun; 161(6):852-60. PubMed ID: 23590693
[TBL] [Abstract][Full Text] [Related]
4. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
Estepp JH; Wiczling P; Moen J; Kang G; Mack JM; Liem R; Panepinto JA; Garg U; Kearns G; Neville KA
Br J Clin Pharmacol; 2018 Jul; 84(7):1478-1485. PubMed ID: 28884840
[TBL] [Abstract][Full Text] [Related]
5. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.
Ware RE; Dertinger SD
Br J Haematol; 2021 Jul; 194(2):252-266. PubMed ID: 33570176
[TBL] [Abstract][Full Text] [Related]
6. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.
Hankins JS; Wynn LW; Brugnara C; Hillery CA; Li CS; Wang WC
Br J Haematol; 2008 Jan; 140(1):80-5. PubMed ID: 17991298
[TBL] [Abstract][Full Text] [Related]
8. Hydroxycarbamide: clinical aspects.
Ware RE
C R Biol; 2013 Mar; 336(3):177-82. PubMed ID: 23643402
[TBL] [Abstract][Full Text] [Related]
9. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.
Flanagan JM; Howard TA; Mortier N; Avlasevich SL; Smeltzer MP; Wu S; Dertinger SD; Ware RE
Mutat Res; 2010 Apr; 698(1-2):38-42. PubMed ID: 20230905
[TBL] [Abstract][Full Text] [Related]
10. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
[TBL] [Abstract][Full Text] [Related]
11. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
F1000Res; 2018; 7():. PubMed ID: 30228870
[TBL] [Abstract][Full Text] [Related]
12. Two assays to evaluate potential genotoxic effects of hydroxyurea in sickle cell disease patients.
Rodríguez A; Kouegnigan L; Ferster A; Cotton F; Duez P
Hemoglobin; 2012; 36(6):545-54. PubMed ID: 23094637
[TBL] [Abstract][Full Text] [Related]
13. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
[TBL] [Abstract][Full Text] [Related]
14. Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia.
Nottage KA; Ware RE; Aygun B; Smeltzer M; Kang G; Moen J; Wang WC; Hankins JS; Helton KJ
Br J Haematol; 2016 Oct; 175(2):331-338. PubMed ID: 27604981
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
[TBL] [Abstract][Full Text] [Related]
16. Hydroxycarbamide treatment in children with Sickle Cell Anaemia is associated with more intact white matter integrity: a quantitative MRI study.
Kapustin D; Leung J; Odame I; Williams S; Shroff M; Kassner A
Br J Haematol; 2019 Oct; 187(2):238-245. PubMed ID: 31215028
[TBL] [Abstract][Full Text] [Related]
17. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
[TBL] [Abstract][Full Text] [Related]
20. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
